دورية أكاديمية
أعرض في EDS

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.

التفاصيل البيبلوغرافية
العنوان: BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
المؤلفون: Mills RJ; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Humphrey SJ; Charles Perkins Centre, School of Life and Environmental Science, The University of Sydney, Sydney 2006, NSW, Australia., Fortuna PRJ; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Lor M; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Foster SR; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Quaife-Ryan GA; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Johnston RL; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Dumenil T; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Bishop C; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Rudraraju R; The WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia; Department of Microbiology and Immunology, The University of Melbourne, Melbourne 3052, VIC, Australia; The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia., Rawle DJ; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Le T; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Zhao W; The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia., Lee L; The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia., Mackenzie-Kludas C; The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia., Mehdiabadi NR; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne 3052, VIC, Australia., Halliday C; Resverlogix Corp., Calgary T3E 6L1, AB, Canada., Gilham D; Resverlogix Corp., Calgary T3E 6L1, AB, Canada., Fu L; Resverlogix Corp., Calgary T3E 6L1, AB, Canada., Nicholls SJ; Victorian Heart Hospital, Monash University, Clayton 3168, VIC, Australia., Johansson J; Resverlogix Corp., San Francisco, CA 94104, USA., Sweeney M; Resverlogix Corp., San Francisco, CA 94104, USA., Wong NCW; Resverlogix Corp., Calgary T3E 6L1, AB, Canada., Kulikowski E; Resverlogix Corp., Calgary T3E 6L1, AB, Canada., Sokolowski KA; Preclinical Imaging Facility, Translational Research Institute, Brisbane, QLD, Australia., Tse BWC; Preclinical Imaging Facility, Translational Research Institute, Brisbane, QLD, Australia., Devilée L; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Voges HK; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Reynolds LT; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Krumeich S; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Mathieson E; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Abu-Bonsrah D; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne 3052, VIC, Australia; Department of Paediatrics, The University of Melbourne, Melbourne 3052, VIC, Australia., Karavendzas K; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne 3052, VIC, Australia., Griffen B; Dynomics Inc., San Mateo, CA 94401, USA; Dynomics Pty Ltd, Brisbane 4000, QLD, Australia., Titmarsh D; Dynomics Inc., San Mateo, CA 94401, USA; Dynomics Pty Ltd, Brisbane 4000, QLD, Australia., Elliott DA; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne 3052, VIC, Australia., McMahon J; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne 3004, VIC, Australia; Department of Infectious Diseases, Monash Medical Centre, Clayton 3168, VIC, Australia., Suhrbier A; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia; GVN Center of Excellence, Australian Infectious Diseases Research Centre, Brisbane, QLD, Australia., Subbarao K; The WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia; The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, VIC, Australia., Porrello ER; Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne 3052, VIC, Australia; Department of Physiology, School of Biomedical Sciences, The University of Melbourne, Melbourne 3052, VIC, Australia., Smyth MJ; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Engwerda CR; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., MacDonald KPA; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia., Bald T; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia; Institute of Experimental Oncology, University Hospital Bonn, Bonn 53127, Germany., James DE; Charles Perkins Centre, School of Life and Environmental Science, The University of Sydney, Sydney 2006, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney 2006, NSW, Australia., Hudson JE; QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia. Electronic address: james.hudson@qimrberghofer.edu.au.
المصدر: Cell [Cell] 2021 Apr 15; Vol. 184 (8), pp. 2167-2182.e22. Date of Electronic Publication: 2021 Mar 16.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4172 (Electronic) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE
أسماء مطبوعة: Publication: Cambridge, Ma : Cell Press
Original Publication: Cambridge, MIT Press.
مواضيع طبية MeSH: COVID-19/*complications , Cardiotonic Agents/*therapeutic use , Cell Cycle Proteins/*antagonists & inhibitors , Heart Diseases/*drug therapy , Quinazolinones/*therapeutic use , Transcription Factors/*antagonists & inhibitors, Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Cell Cycle Proteins/metabolism ; Cell Line ; Cytokines/metabolism ; Female ; Heart Diseases/etiology ; Human Embryonic Stem Cells ; Humans ; Inflammation/complications ; Inflammation/drug therapy ; Mice ; Mice, Inbred C57BL ; Transcription Factors/metabolism ; COVID-19 Drug Treatment
مستخلص: Cardiac injury and dysfunction occur in COVID-19 patients and increase the risk of mortality. Causes are ill defined but could be through direct cardiac infection and/or inflammation-induced dysfunction. To identify mechanisms and cardio-protective drugs, we use a state-of-the-art pipeline combining human cardiac organoids with phosphoproteomics and single nuclei RNA sequencing. We identify an inflammatory "cytokine-storm", a cocktail of interferon gamma, interleukin 1β, and poly(I:C), induced diastolic dysfunction. Bromodomain-containing protein 4 is activated along with a viral response that is consistent in both human cardiac organoids (hCOs) and hearts of SARS-CoV-2-infected K18-hACE2 mice. Bromodomain and extraterminal family inhibitors (BETi) recover dysfunction in hCOs and completely prevent cardiac dysfunction and death in a mouse cytokine-storm model. Additionally, BETi decreases transcription of genes in the viral response, decreases ACE2 expression, and reduces SARS-CoV-2 infection of cardiomyocytes. Together, BETi, including the Food and Drug Administration (FDA) breakthrough designated drug, apabetalone, are promising candidates to prevent COVID-19 mediated cardiac damage.
Competing Interests: Declaration of interests R.J.M., J.E.H., G.A.Q.-R., D.M.T., and E.R.P. are co-inventors on patents relating to cardiac organoid maturation and cardiac therapeutics. J.E.H. is co-inventor on licensed patents for engineered heart muscle. R.J.M., E.R.P., D.M.T., B.G., and J.E.H. are co-founders, scientific advisors, and stockholders in Dynomics. D.M.T. and B.G. are employees of Dynomics. C.H., D.G., L.F., J.J., M.S., N.C.W.W., and E.K. are employees of Resverlogix. S.J.N. received honoraria and research support from Resverlogix. QIMR Berghofer Medical Research Institute filed a patent on the use of BETi.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
التعليقات: Comment in: Nat Rev Cardiol. 2021 Jun;18(6):387. (PMID: 33828252)
References: JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533)
Heart Fail Rev. 2014 Mar;19(2):227-36. (PMID: 23589353)
JAMA Cardiol. 2020 Jul 1;5(7):811-818. (PMID: 32219356)
Lancet. 2020 Feb 15;395(10223):e30-e31. (PMID: 32032529)
Genome Biol. 2018 Feb 6;19(1):15. (PMID: 29409532)
Mol Cancer Ther. 2020 Apr;19(4):1018-1030. (PMID: 32024684)
Circ Res. 1997 Oct;81(4):627-35. (PMID: 9314845)
Sci Signal. 2019 Jan 22;12(565):. (PMID: 30670635)
Cell Syst. 2020 Jul 22;11(1):11-24.e4. (PMID: 32619549)
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8944-9. (PMID: 18574148)
Bioinformatics. 2012 Jun 1;28(11):1530-2. (PMID: 22539670)
Nat Commun. 2018 Jan 26;9(1):391. (PMID: 29374152)
Development. 2017 Mar 15;144(6):1118-1127. (PMID: 28174241)
Circulation. 2020 Dec 15;142(24):2338-2355. (PMID: 33094644)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273. (PMID: 32730619)
Nat Commun. 2018 Apr 10;9(1):1373. (PMID: 29636455)
Circulation. 2017 Sep 19;136(12):1123-1139. (PMID: 28733351)
Circulation. 2013 Jul 23;128(4):377-87. (PMID: 23785004)
Oncotarget. 2017 May 16;8(20):33779-33795. (PMID: 28422713)
Nat Protoc. 2018 Sep;13(9):1897-1916. (PMID: 30190555)
JCI Insight. 2020 Aug 6;5(15):. (PMID: 32603312)
Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106. (PMID: 27924013)
Stem Cells Dev. 2012 Jun 10;21(9):1513-23. (PMID: 21933026)
Cell Stem Cell. 2019 Jun 6;24(6):895-907.e6. (PMID: 30930147)
Science. 2020 Apr 24;368(6489):387-394. (PMID: 32193360)
Cell. 2021 Apr 1;184(7):1895-1913.e19. (PMID: 33657410)
Nat Commun. 2020 Nov 30;11(1):6122. (PMID: 33257679)
Clin Cancer Res. 2019 Jan 1;25(1):300-311. (PMID: 30206163)
Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910)
N Engl J Med. 2020 Jun 11;382(24):2372-2374. (PMID: 32302078)
Circulation. 2021 Mar 9;143(10):1031-1042. (PMID: 33480806)
Circulation. 2020 Nov 24;142(21):2029-2044. (PMID: 33034202)
J Am Coll Cardiol. 2000 Mar 1;35(3):537-44. (PMID: 10716453)
Circulation. 2020 Jul 28;142(4):342-353. (PMID: 32469253)
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8372-E8381. (PMID: 28916735)
Sci Transl Med. 2015 Mar 4;7(277):277ra31. (PMID: 25739765)
Nat Methods. 2011 Oct 23;8(12):1037-40. (PMID: 22020065)
Immunity. 2020 Jul 14;53(1):19-25. (PMID: 32610079)
Circ Heart Fail. 2017 Aug;10(8):. (PMID: 28784688)
Methods Mol Biol. 2018;1711:133-148. (PMID: 29344888)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Nat Biotechnol. 2018 Dec 03;:. (PMID: 30531897)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Nature. 2020 Feb;578(7794):306-310. (PMID: 31969702)
Sci Transl Med. 2017 May 17;9(390):. (PMID: 28515341)
JAMA Cardiol. 2020 Jul 1;5(7):802-810. (PMID: 32211816)
Immunity. 2013 Feb 21;38(2):250-62. (PMID: 23352233)
Nature. 2010 Dec 23;468(7327):1067-73. (PMID: 20871596)
Nat Protoc. 2014;9(6):1514-31. (PMID: 24874816)
J Endocr Soc. 2018 Apr 20;2(5):485-496. (PMID: 29761176)
Trends Pharmacol Sci. 2012 Mar;33(3):154-64. (PMID: 22277298)
Cell Rep Med. 2020 Jul 21;1(4):100052. (PMID: 32835305)
J Biol Chem. 2005 Feb 11;280(6):4037-47. (PMID: 15546885)
Circulation. 2020 Aug 4;142(5):466-482. (PMID: 32403949)
Cardiovasc Diabetol. 2021 Jan 7;20(1):13. (PMID: 33413345)
Nature. 2010 Dec 23;468(7327):1119-23. (PMID: 21068722)
J Mol Cell Cardiol. 2020 Aug;145:25-29. (PMID: 32526224)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
J Clin Invest. 2020 Sep 1;130(9):4740-4758. (PMID: 32484798)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
JAMA. 2020 Apr 28;323(16):1565-1573. (PMID: 32219359)
Nat Rev Drug Discov. 2019 Aug;18(8):609-628. (PMID: 31273347)
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. (PMID: 27141961)
Eur Heart J. 2021 May 14;42(19):1866-1878. (PMID: 33596594)
Circ Res. 2019 Sep 13;125(7):662-677. (PMID: 31409188)
Nat Med. 2020 Jul;26(7):1017-1032. (PMID: 32651579)
Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2021450118. (PMID: 33310900)
Nat Methods. 2015 Feb;12(2):115-21. (PMID: 25633503)
Nat Biotechnol. 2015 Sep;33(9):990-5. (PMID: 26280412)
Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943)
Science. 2020 Sep 4;369(6508):1210-1220. (PMID: 32788292)
Am J Cardiovasc Drugs. 2016 Feb;16(1):55-65. (PMID: 26385396)
Circulation. 2020 Dec 15;142(24):2356-2370. (PMID: 33113340)
J Virol Methods. 1995 Mar;52(1-2):51-4. (PMID: 7539444)
Nat Med. 2020 Oct;26(10):1636-1643. (PMID: 32839624)
Cell Signal. 2017 Oct;38:127-133. (PMID: 28711716)
Nat Rev Cardiol. 2020 Sep;17(9):543-558. (PMID: 32690910)
Cell. 2013 Aug 1;154(3):569-82. (PMID: 23911322)
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20753-20763. (PMID: 32759223)
فهرسة مساهمة: Keywords: Bromodomain and extraterminal family inhibitors; COVID-19; drug discovery; heart; inflammation; organoids
المشرفين على المادة: 0 (BRD4 protein, human)
0 (Cardiotonic Agents)
0 (Cell Cycle Proteins)
0 (Cytokines)
0 (Quinazolinones)
0 (Transcription Factors)
8R4A7GDZ1D (apabetalone)
EC 3.4.17.23 (ACE2 protein, human)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
تواريخ الأحداث: Date Created: 20210403 Date Completed: 20210428 Latest Revision: 20221217
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7962543
DOI: 10.1016/j.cell.2021.03.026
PMID: 33811809
قاعدة البيانات: MEDLINE
الوصف
تدمد:1097-4172
DOI:10.1016/j.cell.2021.03.026